DJIA 16,979.13 0.00 0.00%
NASDAQ 4,526.48 0.00 0.00%
S&P 500 1,986.51 0.00 0.00%
market minute promo

Sarepta Therapeutics (NASDAQ: SRPT)



company name or ticker

Prosensa to Seek U.S. Approval for DMD Drug

Surprising MS Drug Approval: Time to Buy?

The EU has issued a preliminary approval for Translarn, the Duchenne muscular dystrophy drug developed by PTC Therapeutics.

Is Prosensa Holding About to Soar?

Clinical-stage biotechs developing treatments for Duchenne muscular dystrophy have recently won a handful of political battles that have helped their drugs move forward on the regulatory front. Could Prosena be the next company to benefit from this change in political sentiment?

3 Stocks That Soared Stupendously Last Week

These 3 health-care stocks blew away the market this week. Here's how they did it.

Sarepta to Acquire Manufacturing Facility - Analyst Blog

Small Advances for Healthcare Stocks; PTC Therapeutics Rallies After Duchenne Muscular Dystrophy Dru

Small Advances for Healthcare Stocks; PTC Therapeutics Rallies After Duchenne Muscular Dystrophy Drug Approved

Sector Update: Healthcare

PTC Therapeutics Gets Warm Hug From Europe for DMD Drug; Prosensa Rises in Sympathy

Sector Update: Healthcare Shares Mixed; Vertex Up 6% on Positive Coverage

Sector Update: Healthcare

See More Articles...